Nursing,
Journal Year:
2025,
Volume and Issue:
55(3), P. 28 - 35
Published: Feb. 21, 2025
Abstract:
Osteomyelitis
is
characterized
by
inflammation
of
the
bone
tissue,
typically
caused
microorganisms
such
as
bacteria.
It
can
be
challenging
to
treat
and
may
lead
unnecessary
antibiotic
therapies.
Prompt
identification
osteomyelitis
implementation
effective
treatments
are
necessary
eradicate
this
infection.
This
article
discusses
pathophysiology,
clinical
presentation,
diagnosis,
nursing
management
osteomyelitis,
focusing
on
native
Frontiers in Cellular and Infection Microbiology,
Journal Year:
2025,
Volume and Issue:
15
Published: Feb. 28, 2025
Objective
This
study
aimed
to
evaluate
the
effectiveness
of
intravenous
versus
oral
antibiotic
treatments
in
managing
bone
infections,
particularly
osteomyelitis,
using
a
rat
tibial
infection
model.
Methods
A
model
was
established
twelve-week-old
Wistar
rats
via
injection
Staphylococcus
aureus
at
cortical
defect
site.
After
six
weeks,
were
treated
with
vancomycin
(intravenous),
cefazolin
ciprofloxacin
(oral),
or
combined
rifampin
(oral).
Microbial
analysis,
blood
analysis
for
pro-inflammatory
cytokines,
micro-computed
tomography
(μCT),
histological
and
osteoclast
activity
used
assess
efficacy
each
treatment.
Results
Blood
showed
significant
reductions
white
cell
count
cytokines
treatment
groups,
especially
vancomycin.
μCT
imaging
revealed
better
preservation
structure
while
resulted
more
pronounced
structural
deterioration.
confirmed
lower
bacterial
load
vancomycin,
compared
treatments.
Histological
reduced
inflammation,
fibrosis,
minimal
presence
groups.
Osteoclast
notably
indicating
control
resorption.
Conclusion
Intravenous
administration
demonstrated
superior
controlling
infection,
reducing
preserving
While
ciprofloxacin-rifampin
combination
some
efficacy,
they
less
effective
than
likely
due
bioavailability
insufficient
drug
penetration
tissue.
Advanced Science,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 7, 2025
Abstract
Osteomyelitis
represents
a
significant
health
concern,
characterized
by
bacterial
infection
that
can
potentially
present
considerable
challenge
to
clinical
treatment.
Current
treatment
strategies,
including
prolonged
antibiotic
regimens
and
surgical
debridement,
often
fail
adequately
resolve
or
support
bone
regeneration,
largely
due
the
pathogen‐induced
dysregulation
of
microenvironment.
This
study
reports
multifunctional
capsule
achieves
coordinated
capture‐killing
immunomodulatory
within
osseous
tissue,
effectively
resolving
dual
pathological
challenges
persistent
microenvironment
dysregulated
regeneration
inherent
osteomyelitis.
The
capsules,
PC‐O@TOB,
are
based
on
Schiff
base
reaction
procyanidins
(PC)
with
amino
Lysine6‐osteogenic
growth
peptide
(K6‐OGP)
tobramycin
(TOB),
which
allows
for
efficient
loading
controllable
release
K6‐OGP
TOB.
In
vitro
in
vivo
studies
demonstrated
PC‐O@TOB
exhibits
functionality:
potent
bactericidal
activity
through
capture
localized
delivery,
microenvironmental
remodeling
via
ROS
scavenging
M2
macrophage
polarization.
effect
synergizes
capsule's
osteogenic
angiogenic
properties
accelerate
repair.
strategy
antibacterial
later
has
opened
up
new
way
Journal of Functional Biomaterials,
Journal Year:
2025,
Volume and Issue:
16(5), P. 189 - 189
Published: May 21, 2025
Bone
infection
is
a
debilitating
condition
characterized
by
inflammation
of
the
bone
and
its
marrow.
It
poses
significant
challenges
in
clinical
practice
due
to
recalcitrant
nature
difficulty
eradicating
infecting
microorganisms.
Recent
advancements
field
medical
biomaterials
have
shown
hope
treatment
infections.
This
article
reviews
research
progress
for
anti-osteomyelitis
recent
years,
focusing
on
mechanism
action,
unique
advantages,
application
backgrounds
various
materials.
At
same
time,
we
pay
attention
need
materials
used
osteomyelitis
promote
healing.
Infection Control and Hospital Epidemiology,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 4
Published: Oct. 10, 2024
We
conducted
a
retrospective
cohort
study
to
identify
factors
influencing
intravenous
(IV)
versus
oral
antibiotic
therapy
in
first-episode
prosthetic
joint
infections.
Of
the
34/78
(44%)
cases
treated
intravenously,
negative
cultures
(26%),
concomitant
infections
necessitating
IV
antibiotics
(21%),
and
delays
susceptibility
testing
(15%)
were
most
common
reasons
for
therapy.
Antibiotics,
Journal Year:
2023,
Volume and Issue:
12(11), P. 1628 - 1628
Published: Nov. 15, 2023
This
study
aimed
to
compare
clinical
characteristics
and
outcomes
in
patients
with
native
joint
septic
arthritis
(NJSA)
due
methicillin-resistant
Staphylococcus
aureus
(MRSA)
comparison
methicillin-sensitive
S.
(MSSA)
identify
treatment
failure
risk
factors.
We
conducted
a
multi-center
retrospective
on
adult
NJSA
at
three
teaching
hospitals
South
Korea
from
2005
2017.
Among
101
diagnosed
NJSA,
39
(38.6%)
had
MRSA
strains.
Compared
MSSA,
higher
prevalence
of
nosocomial
infections
(17.9%
vs.
1.6%;
p
=
0.005)
received
inappropriate
antibiotics
within
48
h
more
frequently
(74.4%
0%;
<
0.001).
In
total,
twenty
(19.8%)
experienced
failure,
which
encompassed
five
(5.0%)
who
passed
away,
nine
(8.9%)
requiring
repeated
surgical
drainage
after
30
days
antibiotic
therapy,
seven
(6.9%)
relapse.
The
group
showed
rate
overall
(33.3%
11.3%;
0.007)
notably
increased
frequency
interventions
therapy
3.2%,
0.026),
contrast
the
MSSA
group.
Independent
factors
for
included
Charlson
comorbidity
score,
elevated
CRP
levels,
methicillin
resistance.
Methicillin
resistance
is
an
independent
factor
emphasizing
need
vigilant
monitoring
targeted
MRSA-related
cases.
Global & Regional Health Technology Assessment,
Journal Year:
2024,
Volume and Issue:
11(Suppl. 2), P. 5 - 12
Published: July 29, 2024
The
therapeutic
approach
to
the
patient
with
acute
bacterial
skin
and
structure
infection
(ABSSSI)
complicated
infections
often
involves
early
transition
from
intravenous
oral
therapy
(early
switch)
or
discharge.
Our
study
aimed
evaluate
sustainable
innovative
care
models
that
can
be
transferred
community
healthcare
economic
impact
of
dalbavancin
vs
Standard
Care
(SoC)
for
treatment
ABSSSI
other
Gram-positive
including
those
by
multidrug-resistant
organisms.
We
also
described
organization
an
infectious
disease
network
allows
optimizing
complex
dalbavancin.
